Literature DB >> 6653581

Intravenous isosorbide dinitrate in acute left ventricular failure--a dose--response study.

D J Gwilt, M Petri, D S Reid.   

Abstract

The haemodynamic effects of intravenous isosorbide dinitrate (Cedocard) in patients with severe acute left ventricular failure have been assessed using incremental infusion rates from 50 to 800 micrograms min-1. For most patients most of the fall in pulmonary arterial diastolic pressure occurred by 200 micrograms min-1, with little further fall at higher doses. At 200 micrograms min-1 pulmonary arterial diastolic pressure fell from 29 to 23 mgHg (P less than 0.001), there was no significant change in cardiac index (1.9 to 2.0 L min-1 m-2) or heart rate (108 to 108 beats min-1). Despite high doses, no side effects were observed. Intravenous isosorbide dinitrate is effective and safe in the management of acute severe left ventricular failure. In most patients an infusion rate of about 200 micrograms min-1 produces optimal haemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653581     DOI: 10.1093/oxfordjournals.eurheartj.a061383

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

Review 1.  An update on nitrate tolerance: can it be avoided?

Authors:  S R Maxwell; M J Kendall
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

2.  The haemodynamic effects of sublingual nitroglycerin spray in severe left ventricular failure.

Authors:  J D Edwards; P T Grant; P Plunkett; P Nightingale
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

Review 3.  Haemodynamic aspects of nitrate tolerance.

Authors:  L Erhardt
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.

Authors:  D Vogt; D Trenk; R Bonn; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.